Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04409509

Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)

Coronavirus Disease 2019 (COVID-19) Clinical Trial

Official title:
A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19)

Clinical Trial Summary

This is a prospective, phase 2, multicenter, randomized, double blind, placebo controlled, parallel group study to assess the safety and efficacy of CSL312 administered intravenously, in combination with standard of care (SOC) treatment, in patients with Coronavirus disease 2019 (COVID 19)

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04409509
Study type Interventional
Source CSL Behring
Contact
Status Completed
Phase Phase 2
Start date July 1, 2020
Completion date January 12, 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT04516564 - A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects Phase 1
Withdrawn NCT04519424 - CSL324 in COVID-19 Phase 2
Not yet recruiting NCT04395170 - Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19. Phase 2/Phase 3
Completed NCT05437289 - A Study to Evaluate the Safety and Tolerability of AZD7442 in Healthy Chinese Adults Phase 1
Completed NCT05594147 - An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib
Withdrawn NCT04848467 - COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older Phase 3
Completed NCT04588363 - COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C
Terminated NCT04877743 - Non-Interventional Enhanced Active Surveillance Study of Adults Vaccinated With AZD1222
Completed NCT04742725 - A Study to Evaluate the Efficacy and Safety of Prothione™ Capsules for Mild to Moderate Coronavirus Disease 2019 (COVID-19) Phase 2
Completed NCT04545047 - Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19
Completed NCT04375761 - COVID-19: Human Epidemiology and Response to SARS-CoV-2
Completed NCT04378777 - Immunophenotyping Assessment in a COVID-19 Cohort
Completed NCT04327206 - BCG Vaccination to Protect Healthcare Workers Against COVID-19 Phase 3
Terminated NCT05375760 - A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19 Phase 2
Completed NCT04344977 - Collection of Anti-SARS-CoV-2 Immune Plasma
Terminated NCT04389840 - Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure Phase 2/Phase 3
Withdrawn NCT04425733 - MK-5475 in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009) Phase 1
Not yet recruiting NCT04438837 - Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers N/A
Completed NCT04275245 - Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia Phase 1/Phase 2
Terminated NCT04638634 - Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects Phase 1